Exploring Clinical Outcomes with a BCL2 Inhibitor for the Treatment of Acute Myeloid Leukemia (AML)
Thursday, November 9, 2023 at 2-3 pm ET Pricing: Free for Members and Non-Members
Please note that this session is not accredited for continuing pharmacy education credit.
This webinar explores the evolution of the treatment landscape, clinical outcomes, and practical management of a BCL2-Inhibitor. The content of this webinar is intended for US Formulary Decision Makers.
- Review the AML disease state and evolving treatment landscape.
- Describe the efficacy and safety of BCL2-inhibitor treatment in newly diagnosed AML unfit for intensive chemotherapy.
- Provide an overview of the practical management of AML patients receiving BCL2-inhibitor treatment.
This webinar is sponsored and developed by Abbvie US Medical Affairs. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.
For individuals from the media/press interested in attending, please email email@example.com.
Ryan Beechinor, PharmD, BCPS, BCOP
Clinical Assistant Professor, UCSF School of Pharmacy
Senior Pharmacist Hematology/Oncology
UC Davis Comprehensive Cancer Center